Clinical Review
Non-alcoholic fatty liver disease
BMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g4596 (Published 29 July 2014) Cite this as: BMJ 2014;349:g4596
Related articles
- Endgames Published: 03 August 2015; BMJ 351 doi:10.1136/bmj.h4023
See more
- Cholera: Malawi is in grip of its deadliest outbreakBMJ February 09, 2023, 380 p328; DOI: https://doi.org/10.1136/bmj.p328
- Emergency care is in “dire” situation after loss of NHS beds, says royal collegeBMJ May 31, 2022, 377 o1376; DOI: https://doi.org/10.1136/bmj.o1376
- GP efforts to cut antibiotic use failed to curb spread of drug resistant E coli, evaluation findsBMJ August 05, 2021, 374 n1953; DOI: https://doi.org/10.1136/bmj.n1953
- Check covid status when planning emergency bowel surgery, doctors are toldBMJ March 11, 2021, 372 n695; DOI: https://doi.org/10.1136/bmj.n695
- Capsule endoscopies will be trialled in EnglandBMJ March 11, 2021, 372 n692; DOI: https://doi.org/10.1136/bmj.n692
Cited by...
- Microbiota-Immune Interactions Regulate Metabolic Disease
- Young onset diabetes in Asian Indians is associated with lower measured and genetically determined beta-cell function: an INSPIRED study
- The effect of green Mediterranean diet on cardiometabolic risk; a randomised controlled trial
- Prospective association between adherence to the Mediterranean diet and hepatic steatosis: the Swiss CoLaus cohort study
- Predicting and elucidating the etiology of fatty liver disease using a machine learning-based approach: an IMI DIRECT study
- Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia
- Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis
- Liver Function and Risk of Type 2 Diabetes: Bidirectional Mendelian Randomization Study
- Metabolic disturbances of non-alcoholic fatty liver resemble the alterations typical for type 2 diabetes
- A patient request for some "deprescribing"
- Unselective screening for liver disease may not be cost effective